AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06576245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quantum Molecular Resonance (QMR) Therapy
Description: Quantum Molecular Resonance (QMR) therapy will be administered using the RexonEye® device (Resono Ophthalmic, Trieste, Italy). The device delivers low-intensity, high-frequency electrical waves ranging from 4-64 MHz through specialized contact electrodes. Participants will receive 4 QMR treatment sessions over 6 weeks. Each session lasts for 20 minutes, with a 30-second alternation between the eyes. The goal of QMR therapy is to stimulate cellular regeneration and improve tear production by targeting the lacrimal gland.
Study NCT06576245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL) Therapy
Description: Intense Pulsed Light (IPL) therapy will be performed using the OptiLIGHT® device (Lumenis Be Ltd., Yokneam, Israel). IPL treatment involves the application of high-intensity, non-coherent, polychromatic light within the 500 to 1200 nm wavelength spectrum. Participants will receive 3 IPL sessions over 6 weeks, with sessions targeting the periocular area and upper eyelids to improve meibomian gland function. Each session includes the application of 50 light pulses to the periocular area and upper eyelids using specified parameters (e.g., fluence 14 J/cm² for the periocular area, fluence 11 J/cm² for the upper eyelids).
Study NCT06576245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tear Substitute Treatment (Supportive Therapy)
Description: All participants will also receive supportive therapy with tear substitutes throughout the study period. This includes:~Idroflog® (0.2% Hyaluronic Acid with 0.001% Hydrocortisone): Applied 3 times per day.~VisuXL gel® (Cross-linked Carboxymethyl Cellulose with Coenzyme Q10): Applied once a day.~Artelac® Nighttime Gel (0.24% Sodium Hyaluronate with Carbomer): Applied before sleeping. These tear substitutes are intended to provide symptomatic relief and support tear film stability during the treatment period.
Study NCT06340620 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic ultrasound examination
Description: Endoscopic ultrasound examination will be performed.
Study NCT05622669 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Sensed and lived experience data from all groups without a specific behavioural or drug intervention
Study NCT06471205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion on D1 and D8, or D1 for a cycle of 3 weeks.
Study NCT06471205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Monoclonal Antibody
Description: Administration by intravenous infusion for a cycle of 3 weeks (Q3W).
Study NCT05110885 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: A questionnaire prepared by the researchers will be presented to the group.
Study NCT04868266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: end tidal carbon dioxide monitoring
Description: We will monitor end tidal carbon dioxide with capnography during minimal sedation
Study NCT05895266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903
Description: Oral Tablet
Study NCT05895266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral Liquid
Study NCT06088264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986322
Description: Specified dose on specified days.
Study NCT05741801 — intervention group
Intervention type: OTHER
Intervention: interviews
Description: observations of healthcare professionals working in hospitals (outreach/sepsis team), one-on-one interviews with healthcare professionals, and focus groups or interviews with ex-patients/family members.
Study NCT06241274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moxibustion
Description: Subjects received moxibustion covering Shenque, Zhonggong, Guanyuan, and Qihai for 30 minutes every day for 14 days.
Study NCT06241274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptomatic supportive treatment
Description: Symptomatic supportive treatment.
Study NCT05557045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP815
Description: JZP815 will be administered as oral capsules to participants BID approximately 12 hours apart, in the morning and in the evening. QD dosing may also be investigated, if supported by PK data.
Study NCT04991168 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Two questionnaires used to assess the state of knowledge and practices in oral health. An oral assessment will be carried out for voluntary patients.
Study NCT04215679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three-dimensional immersive virtual reality application
Description: In this group, individuals will be included in a game program that will last for 3 days a week for a total of 6 weeks and 45 minutes a day. Individuals will use the IVR to rehabilitate functions that are frequently used in daily life through task-oriented games. The IVR device will be placed on the head of the individual by closing the eyes of the individual and the Leap Motion device will be used to enable individuals to see their own hands in a virtual reality environment. In order to ensure the safety of individuals, practices shall be carried out with the individual sitting in the chair and leaning against the back. A total of 3 different games will be used for upper extremity function, each game will be 15 minutes and the total session time will be 45 minutes.
Study NCT04215679 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor imagery
Description: Motor imagery will be performed with the eyes closed. In addition, for the safety of the individual, the individual will sit comfortably in a chair in a quiet environment and sit back. In the motor imagery group, individuals will be shown videos of the 3 games for 2 times in the IVR group and will be asked to imagine that they perform the same functions in the IVR games. The motor imagery will be 3 days a week for a total of 6 weeks and 45 minutes per day (including rest periods).
Study NCT04215679 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Individuals in this group will be randomly recruited from hospitalized stroke volunteers. Since these individuals receive routine rehabilitation 5 days a week, they will be evaluated at the beginning and end of 18 sessions over a total period of 6 weeks. Conventional physiotherapy will include normal joint movements, muscle strengthening exercises, balance and mobility exercises, and exercises to improve daily life activity.
Study NCT06441565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fruquintinib
Description: A treatment cycle of 4 weeks, with 4 mg orally once daily for 3 weeks, followed by a 1-week break
Study NCT06441565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: A treatment cycle of 4 weeks, with 4 mg orally once daily for 3 weeks, followed by a 1-week break
Study NCT06441565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 2.8 g/m² (400mg bolus + 2.4g/m² continuous infusion) given every 2 weeks through hepatic arterial infusion
Study NCT06441565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m² given every 2 weeks through hepatic arterial infusion
Study NCT04517006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-focused acts
Description: Completion of daily acts for personal enjoyment.
Study NCT04517006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prosocial acts
Description: Completion of daily acts for the benefit of others.
Study NCT06429176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPL84
Description: SPL84 solution for nebulization
Study NCT06429176 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for nebulization
Study NCT05414591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001 drug A
Description: 1 tablet, Oral, once daily single dose
Study NCT05414591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001 drug B
Description: 3 tablet, Oral, once daily single dose
Study NCT05372068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concrete household floor
Description: Household soil floors will be replaced with concrete floors
Study NCT05052801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemarituzumab
Description: Intravenous (IV) infusion
Study NCT05052801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: mFOLFOX6 administered as a combination of oxaliplatin and leucovorin as IV infusions. 5-FU administered as bolus followed by additional administration as IV infusion.
Study NCT05034211 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Programmed intermittent bolus epidural
Description: one arm will receive programmed intermittent boluses of local anesthetic via the epidural catheter on fixed time intervals. Standard 27G Tuohy needle epidural set with epidural catheter insertion on L2-L3 site, with the patient either sitting or in the lateral decubitus position will be used. Local injection with 6 ml lidocaine 2% will be performed before the insertion of the epidural needle
Study NCT05034211 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Provider administered analgesia on patient request
Description: one arm will receive bolus of local anesthetic via the catheter upon patient request. Standard 27G Tuohy needle epidural set with epidural catheter insertion on L2-L3 site, with the patient either sitting or in the lateral decubitus position will be used. Local injection with 6 ml lidocaine 2% will be performed before the insertion of the epidural needle
Study NCT05052801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: mFOLFOX6 administered as a combination of oxaliplatin and leucovorin as IV infusions. 5-FU administered as bolus followed by additional administration as IV infusion.
Study NCT05052801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study NCT06084338 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic ablative radiotherapy
Description: Metastasis directed
Study NCT05028582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARQ-154 Foam 0.3%
Description: ARQ-154 Foam 0.3%
Study NCT06084338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pluvicto
Description: PSMA targeted radiopharmaceutical therapy
Study NCT06084338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical testosterone
Description: Topical testosterone 1.62% gel
Study NCT06116903 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling for testing of the detection of molecular abnormalities in exosomes of glial tumors
Study NCT06641869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: procyanidin C1
Description: Proprietarily extracted procyanidin C1
Study NCT06641869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cellumiva
Description: Cellumiva is a novel senolytic complex blend invented by Mrs. Patricia Mayer. It's a complext of grape seed extract(its key active component later identified asPCC1), Pterostilbene and Spermidine.
Study NCT06641869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05249959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C))
Description: Standard Induction phase (cycle 1-2 of R-BAC every 28 days according to the following schedule):~* Rituximab 375 mg/m2 i.v. Day 1~* Bendamustine 70 mg/m2, Days 2 and 3~* Cytarabine 500 mg/m2, Day 2-4~After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:~CONSOLIDATION PHASE:~* 2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by~* 2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks
Study NCT05249959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)
Description: Reduced Induction phase (cycle 1-2 with two different schedules for patients deemed FRAIL or UNFIT for standard induction therapy,based on protocol dose and as per medical judgment are allowed).~* Rituximab 375 mg/m2 i.v. Day 1~* Bendamustine 70 mg/m2, Days 2 and 3~* Cytarabine 500 mg/m2, Day 2 and 3~or~* Rituximab 375 mg/m2 i.v. Day 1~* Bendamustine 100 mg, Days 2 and 3~* Cytarabine 500 mg, Day 2 and 3~After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:~CONSOLIDATION PHASE:~* 2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by~* 2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks
Study NCT04339036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine Oral Product
Description: Capecitabine 750 mg/m2 twice daily orally for 14 days
Study NCT04339036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide Oral Product
Description: temozolomide 200 mg/m2 orally on Days 10-14, with 14 days between cycles
Study NCT04339036 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: transarterial radioembolization
Description: Trans-arterial radioembolization (TARE) on Day 7 of cycle 2 and, if needed for the other lobe, Day 7 of either cycle 3 or 4.
Study NCT04977024 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine
Description: Receive SOC mRNA SARS-CoV-2 vaccine IM
Study NCT04977024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04977024 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1
Description: Given IM
Study NCT05979922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Coping
Description: Participants will receive the Caring Mind mobile app containing the Mindfulness-based Cognitive Coping program.
Study NCT05979922 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Educational/Resources Program
Description: Participants will receive a traditional educational/resources program, containing a downloadable workbook and online resources.
Study NCT05028582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARQ-154 Vehicle
Description: Vehicle
Study NCT04956601 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: vaginal brachytherapy/pelvic external beam radiotherapy
Description: high-dose-rate vaginal brachytherapy; pelvic external beam radiotherapy
Study NCT04956601 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: vaginal brachytherapy/pelvic external beam radiotherapy
Description: high-dose-rate vaginal brachytherapy; pelvic external beam radiotherapy
Study NCT06549452 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mHealth Intervention
Description: Our HIPPA-compliant texting platform is linked to the Fitabase Interface. Real time activity data are transmitted from the participant's smartphone to Fitabase via cellular network. Participants will receive 3-5 texts/day in sync with their preferred schedule defined at enrollment and taking into account school schedules as relevant. These texts use personal, disease-specific, and provider information to deliver two types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
Study NCT06549452 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Usual Care
Description: Routine medical care
Study NCT03733262 — intervention group
Intervention type: OTHER
Intervention: De-prescribing Trial
Description: Validated de-prescribing algorithms will be applied for any patients identified as taking one of the 9 study drugs in order to determine whether or not physician should consider a deprescribing trial. If they are are identified as candidates for deprescribing and consent to participate in the trial, they will enter the Deprescribing Trial group and begin the deprescribing trial.
Study NCT05184595 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carfilzomib delivered in OH only
Description: Patients receive the whole treatment en OH.
Study NCT05184595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carfilzomib delivered in OH and HaH combined
Description: Patients receive the first cycle of treatment in OH. Then, they are randomized between exclusive OH treatment and combined treatment in OH and at home with HaH services.
Study NCT05072340 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resilience Skills Enhancement (RISE)
Description: The RISE training was developed according to theory, empirical evidence and contextual information. The contents, components, pedagogy, and technical elements of RISE is established based on the resilience theory (Szanton \& Gill, 2010) systematic review and meta-analysis, meta-synthesis, and qualitative study (Ang et al., 2021). Ethical and quality standards was assessed using the Health on the Net code of conduct and the Health-Related Website Evaluation Form respectively. The overall rating of the designed RISE is more than 75% of the total possible points to ensure quality of website by three research team members.
Study NCT05072340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience Skills Enhancement (RISE)
Description: The RISE training was developed according to theory, empirical evidence and contextual information. The contents, components, pedagogy, and technical elements of RISE is established based on the resilience theory (Szanton \& Gill, 2010) systematic review and meta-analysis, meta-synthesis, and qualitative study (Ang et al., 2021). Ethical and quality standards was assessed using the Health on the Net code of conduct and the Health-Related Website Evaluation Form respectively. The overall rating of the designed RISE is more than 75% of the total possible points to ensure quality of website by three research team members.
Study NCT06287671 — intervention group
Intervention type: PROCEDURE
Intervention: Colorectal resection or stoma closure
Description: Elective open or minimally invasive resection for colorectal cancer, IBD or other benign colorectal disorder, or stoma closure
Study NCT05906615 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine IV
Description: Administration of IV lidocaine will take place according to the standard protocol as is currently already used in daily clinical practice. First, a lidocaine bolus of 1.5mg/kg is administered, followed by a continuous infusion of 1.5mg/kg/hour. When no pain relief is noticed, each 15 minutes the dose is raised with 1ml up to a maximum of 2mg/kg/hour. If again no pain relief is noticed, the anesthesiologist is consulted. When the anesthesiologist agrees, and no side effects occur, lidocaine infusion can be increased up to a maximum of 2.5mg/kg/hour, with a maximum of 250mg/hour. When there is a pain response - pain is reduced with at least two NRS points or 30% from baseline - that dose is administered for two hours continuously. Following treatment the patient will be observed for an hour before leaving the hospital or recovery unit, again, all according to current daily clinical practice.
Study NCT05598450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS and MEG for auditory hallucinations via self controlled clinical trials
Description: a 4 weeks, weekly 345（23min\*3times\*5day） minutes, 1Hz, 100%RMT-rTMS protocol~Detail precedure:~Before intervention, each patient was scheduled to collect three magnetoencephalogram data sessions. Apply MEG technology to calculate possible locations and determine three intervention targets. Pseudo stimulation in the first week, 5-day intervention, 3 targets per day, each target for 23 minutes, with a 30 minute interval between each target. Evaluate the scale after the first week of pseudo stimulation. Week 2-4 real stimulation, intervention 5 days a week, 3 targets per day, each target for 23 minutes, with a 30 minute interval between each target. After the end of the fourth week, evaluate the scale. And follow-up evaluations will be conducted on the 7th, 14th, 30th, 60th, and 90th days after the intervention.
Study NCT06578598 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Igelplus
Description: Intubation with Igelplus laryngeal mask
Study NCT06578598 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Igelplus
Description: Intubation with Igelplus laryngeal mask
Study NCT05899283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCI-HF160
Description: OCI-HF160 are used in patients for hemofiltration, hemodialysis and hemodiafiltration, to correct solute and fluid imbalances in patients' blood.
Study NCT05899283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FX800HDF
Description: FX800HDF are used in patients for hemofiltration, hemodialysis and hemodiafiltration, to correct solute and fluid imbalances in patients' blood.
Study NCT05044078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autogenic Inhibition MET
Description: If a sub-maximal contraction of the muscle is followed by stretching of the same muscle it is known as Autogenic Inhibition MET.